Abraham, Fruchter & Twersky LLP Notifies Shareholders of a Class Action Lawsuit on Behalf of Investors who Acquired Shares of Block, Inc. (NYSE: XYZ)NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (www.aftlaw.com), a nationally recognized securities fraud class action law firm announces that purchasers of Block, Inc. (
NYSEXYZ) Class A common stock between February 26, 2020 and April 30, 2024, inclusive (the “Class Period”), have until March 18, 2025 to seek appointment as lead plaintiff of the Block securities fraud class action captioned Gonsalves v. Block, Inc., No. 25-00642 (N.D. Cal.).
Abraham, Fruchter & Twersky LLP Notifies Shareholders of a Class Action Lawsuit on Behalf of Investors who Acquired Shares of Akero Therapeutics, Inc. (NYSE: AKRO)NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (www.aftlaw.com), a nationally recognized law firm that focuses on protecting investors’ rights, informs shareholders of a class action lawsuit on behalf of investors who purchased Akero Therapeutics, Inc. (“Akero”) (
NYSEAKRO) common stock captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.).
MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc. (NASDAQ:MORF)NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors’ rights, is investigating whether Morphic Holding, Inc. (
NASDAQMORF), a biopharmaceutical company, violated U.S. federal securities laws by making false or misleading statements or failing to timely disclose material information to investors.
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors’ rights, is investigating whether Akero Therapeutics (
NASDAQAKRO), a clinical-stage biotechnology company, violated U.S. federal securities laws by making false or misleading statements or failing to timely disclose material information to investors.
Abraham, Fruchter & Twersky LLP Notifies Shareholders of a Class Action Lawsuit on Behalf of Investors who Acquired Shares of AT&T Inc. (NYSE: T)NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (www.aftlaw.com), a nationally recognized law firm that focuses on protecting investors’ rights, announces its filing of a class action lawsuit on behalf of investors who purchased AT&T common stock captioned General Retirement System of the City of Detroit v. AT&T Inc., No. 23-cv-07351 (S.D.N.Y.).
Abraham, Fruchter & Twersky LLP Notifies Shareholders of a Class Action Lawsuit on Behalf of Investors who Acquired Shares of Verizon Communications Inc. (NYSE: VZ)NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (www.aftlaw.com), a nationally recognized law firm that focuses on protecting investors’ rights, announces its filing of a class action lawsuit on behalf of investors who purchased Verizon common stock captioned General Retirement System of the City of Detroit v. Verizon Communications, Inc., No. 23-cv-05218 (D.N.J.).
